Skip to main content

SET8 Inhibition Potentiates Radiotherapy by Suppressing DNA Damage Repair in Carcinomas.

Publication ,  Journal Article
Pan, D; Du, YR; Li, R; Shen, AH; Liu, XD; Li, CY; Hu, BR
Published in: Biomed Environ Sci
March 20, 2022

OBJECTIVE: SET8 is a member of the SET domain-containing family and the only known lysine methyltransferase (KMT) that monomethylates lysine 20 of histone H4 (H4K20me1). SET8 has been implicated in many essential cellular processes, including cell cycle regulation, DNA replication, DNA damage response, and carcinogenesis. There is no conclusive evidence, however, regarding the effect of SET8 on radiotherapy. In the current study we determined the efficacy of SET8 inhibition on radiotherapy of tumors and the underlying mechanism. METHODS: First, we explored the radiotherapy benefit of the SET8 expression signature by analyzing clinical data. Then, we measured a series of biological endpoints, including the xenograft tumor growth in mice and apoptosis, frequency of micronuclei, and foci of 53BP1 and γ-H2AX in cells to detect the SET8 effects on radiosensitivity. RNA sequencing and subsequent experiments were exploited to verify the mechanism underlying the SET8 effects on radiotherapy. RESULTS: Low expression of SET8 predicted a better benefit to radiotherapy in lung adenocarcinoma (LUAD) and invasive breast carcinoma (BRCA) patients. Furthermore, genetic deletion of SET8 significantly enhanced radiation treatment efficacy in a murine tumor model, and A549 and MCF7 cells; SET8 overexpression decreased the radiosensitivity. SET8 inhibition induced more apoptosis, the frequency of micronuclei, and blocked the kinetics process of DNA damage repair as 53BP1 and γ-H2AX foci remained in cells. Moreover, RNF8 was positively correlated with the SET8 impact on DNA damage repair. CONCLUSION: Our results demonstrated that SET8 inhibition enhanced radiosensitivity by suppressing DNA damage repair, thus suggesting that SET8 potentiated radiotherapy of carcinomas. As new inhibitors of SET8 are synthesized and tested in preclinical and clinical settings, combining SET8 inhibitors with radiation warrants consideration for precise radiotherapy.

Duke Scholars

Published In

Biomed Environ Sci

DOI

EISSN

2214-0190

Publication Date

March 20, 2022

Volume

35

Issue

3

Start / End Page

194 / 205

Location

China

Related Subject Headings

  • Toxicology
  • Radiotherapy
  • Mice
  • Humans
  • Histone-Lysine N-Methyltransferase
  • Hela Cells
  • HeLa Cells
  • DNA Replication
  • DNA Damage
  • Cell Line, Tumor
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Pan, D., Du, Y. R., Li, R., Shen, A. H., Liu, X. D., Li, C. Y., & Hu, B. R. (2022). SET8 Inhibition Potentiates Radiotherapy by Suppressing DNA Damage Repair in Carcinomas. Biomed Environ Sci, 35(3), 194–205. https://doi.org/10.3967/bes2022.028
Pan, Dong, Ya Rong Du, Rong Li, Ai Hua Shen, Xiao Dong Liu, Chuan Yuan Li, and Bu Rong Hu. “SET8 Inhibition Potentiates Radiotherapy by Suppressing DNA Damage Repair in Carcinomas.Biomed Environ Sci 35, no. 3 (March 20, 2022): 194–205. https://doi.org/10.3967/bes2022.028.
Pan D, Du YR, Li R, Shen AH, Liu XD, Li CY, et al. SET8 Inhibition Potentiates Radiotherapy by Suppressing DNA Damage Repair in Carcinomas. Biomed Environ Sci. 2022 Mar 20;35(3):194–205.
Pan, Dong, et al. “SET8 Inhibition Potentiates Radiotherapy by Suppressing DNA Damage Repair in Carcinomas.Biomed Environ Sci, vol. 35, no. 3, Mar. 2022, pp. 194–205. Pubmed, doi:10.3967/bes2022.028.
Pan D, Du YR, Li R, Shen AH, Liu XD, Li CY, Hu BR. SET8 Inhibition Potentiates Radiotherapy by Suppressing DNA Damage Repair in Carcinomas. Biomed Environ Sci. 2022 Mar 20;35(3):194–205.

Published In

Biomed Environ Sci

DOI

EISSN

2214-0190

Publication Date

March 20, 2022

Volume

35

Issue

3

Start / End Page

194 / 205

Location

China

Related Subject Headings

  • Toxicology
  • Radiotherapy
  • Mice
  • Humans
  • Histone-Lysine N-Methyltransferase
  • Hela Cells
  • HeLa Cells
  • DNA Replication
  • DNA Damage
  • Cell Line, Tumor